| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Lesofavumab
CAS:1807960-57-1
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Lesofavumab
CAS:1807960-57-1
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Lesofavumab (DVV03805)
CAS:1807960-57-1
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Lesofavumab Basic information |
| Product Name: | Lesofavumab | | Synonyms: | Lesofavumab;Research Grade Lesofavumab (DVV03805);Research Grade Lesofavumab | | CAS: | 1807960-57-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lesofavumab Structure]() |
| | Lesofavumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lesofavumab Usage And Synthesis |
| Uses | Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1]. | | in vivo | Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) is able to protect mice against lethal challenge of the mutant influenza B virus[2]. | Animal Model: | DBA/2J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2] | | Dosage: | 15 mg/kg | | Administration: | Intravenous administration, single dose, 24, 48 or 72h post infection | | Result: | Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48h. Even when given at 72h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969. |
| | References | [1] Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421. DOI:10.1093/toxsci/kfz053
[2] Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234. DOI:10.1038/ncomms14234 |
| | Lesofavumab Preparation Products And Raw materials |
|